Evonik Signals Stronger Earnings Without Budging on BASF

Evonik has given shareholders two distinct threads to pull on this week: a firmer earnings trajectory and an unchanged stance toward BASF. The specialty chemicals group now expects full-year results at the upper end of its guidance corridor, while continuing to rebuff takeover talks with its larger rival — a pair of signals that demand separate reading.

Guidance Sharpens, Ceiling Holds

For 2026, Evonik anticipates adjusted EBITDA in the upper half of its €2.0bn to €2.2bn range, according to Reuters. The company also projects fourth-quarter earnings above the prior-year level. Crucially, this is a refinement within the existing corridor, not an upgrade — the upper bound stays put. The outlook points to a stronger earnings position without promising a leap beyond the current framework.

That distinction matters because the market's bar remains high. In the third quarter, adjusted EBITDA climbed 40% year on year to €629m, just shy of the €633.2m analyst consensus cited by Reuters. Solid growth and a narrow miss sit side by side, which is why the confidence expressed for the closing quarter carries particular weight.

BASF: Information, Not Negotiation

Running parallel to the operating story is Evonik's posture toward BASF. The executive board has rejected takeover negotiations, stating that BASF's offer "in its current form" is not in the best interest of Evonik and its stakeholders. The wording targets the proposal as submitted — it is neither consent to further talks nor a blanket verdict on every conceivable transaction structure.

Should investors sell immediately? Or is it worth buying Evonik?

What Evonik has offered instead is a confidential exchange, strictly for information purposes. The board has drawn a clear line between sharing information behind closed doors and negotiating over a concrete bid; only the former has been signalled. Management continues to prioritise developing Evonik as an independent company.

The price tag attached to BASF's proposal — raised roughly two weeks ago to €24 per share, per media reports — does not appear in Evonik's own ad-hoc release. That figure should therefore be kept apart from the board's confirmed position, which is simply the rejection of the offer as presented. Share price moves alone, meanwhile, cannot be read as evidence of rapprochement between the two companies or of any shift in Evonik's stance.

Two Yardsticks, No Common Ground

On the other side of the table, BASF chief executive Markus Kamieth has stressed his company's price discipline. Reuters reported on Wednesday that BASF will not acquire Evonik at any price and would pursue a deal only if it creates value for BASF shareholders. The two sides are thus measuring the same transaction against different standards: Evonik against the interests of the company and its stakeholders, BASF against value for its own investors. Against that split, the confidential information channel is no confirmed entry into takeover negotiations.

Evonik at a turning point? This analysis reveals what investors need to know now.

A higher reported aggregate stake in Evonik adds another facet to the shareholder structure, though it does not by itself imply support for the takeover effort. The stock posted a daily move of -2.2% yesterday, a price change that is chronologically separate from the earnings figures published today.

Two independent questions now frame the investment case: whether Evonik delivers on its more confident earnings outlook, and whether anything changes in its position on takeover negotiations. The next confirmed corporate date is the Q3 2026 quarterly statement on 03.11.2026. Until then, the board's declared course — independent development, with negotiations over the submitted proposal declined — remains the benchmark.

Ad

Evonik Stock: New Analysis - 3 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...